Edward Newman

Associate Professor
Cancer Biology
Beckman Research Institute
United States of America

Professor Oncology
Biography

Dr. Newman's research concentrates on developing novel DNA methyltransferase inhibitors for cancer therapy

Research Intrest

Cancer Biology Developmental Cancer Therapeutics Program Comprehensive Cancer Center Co-leaders Early Therapeutic Disease Team Leukemia Disease Team Lymphoma Disease Team

List of Publications
CD30 downregulation, MMAE resistance, and MDR1 upregulation are all associated with resistance to brentuximab vedotin
Newman EM, Morgan RJ, Kummar S, Beumer JH, Blanchard MS, Ruel C, El-Khoueiry AB, Carroll MI, Hou JM, Li C, Lenz HJ. A phase I, pharmacokinetic, and pharmacodynamic evaluation of the DNA methyltransferase inhibitor 5-fluoro-2′-deoxycytidine, administered with tetrahydrouridine. Cancer chemotherapy and pharmacology. 2015 Mar 1;75(3):537-46.